Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Pfizer Inc. closed $4.92 short of its 52-week high ($31.54), which the company reached on July 30th.

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to ...

The article " Pfizer: 4 Reasons to Buy This Stock " first appeared on MarketBeat.

Pfizer Inc. closed $5.01 below its 52-week high ($31.54), which the company reached on July 30th.

AI stocks are stealing the spotlight today as the appetite for these services continues to gain traction globally.

Pfizer Inc. defeated a lawsuit from Texas Attorney General Ken Paxton that alleged the pharmaceutical giant misrepresented ...

Sangamo Therapeutics Inc. fell as much as 67% in extended trading after Pfizer Inc. ended its partnership to develop a new ...

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

A once-groundbreaking sickle cell disease drug — at the center of a $5.4 billion acquisition two years ago — is the subject ...

Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A program. While it was another big loss to ...